ArticleCell2020
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04854876 (An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against SARS-CoV-2 Virus Infection), which is not on this map. Cited by 207 papers.
0numbers the graph read from it
0cells of the map it votes in
207citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against SARS-CoV-2 Virus Infection
Who cites it
207 citing papers in PubMed, 397 citations in OpenAlex.
- SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19.The Journal of clinical investigation · 2021Trial
- Protective near-germline antibodies to malaria elicited by RTS,S/AS01bioRxiv : the preprint server for biology · 2026Article
- Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332Nature immunology · 2026Article
- Integrated humoral and inflammatory signatures predict outcomes in severe COVID-19: a 14-day longitudinal analysis.Clinical & translational immunology · 2026Article
- Identification of a broad and potent V3 glycan site bNAb targeting an N332bioRxiv : the preprint server for biology · 2025Article
- Regulators and Conductors of Immunity: Natural Immune System in Health and Autoimmunity.International journal of molecular sciences · 2025Review
- Imprints of somatic hypermutation on B-cell receptor immunoglobulins post-infection versus post-vaccination against SARS-CoV-2.ImmunoHorizons · 2025Article
- Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Review
- Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles.bioRxiv : the preprint server for biology · 2025Article
- A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.Journal of virology · 2024Article
- Identification of virus epitopes and reactive T-cell receptors from memory T cells without peptide synthesis.Communications biology · 2024Article
- Antibodies in neurological diseases: Established, emerging, explorative.Immunological reviews · 2024Review
- Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans.NPJ vaccines · 2024Article
- Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.PLoS pathogens · 2024Article
- Computational detection of antigen-specific B cell receptors following immunization.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Combining mutation and recombination statistics to infer clonal families in antibody repertoires.eLife · 2024Article
- The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2.PLoS pathogens · 2024Article
- Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2.Communications biology · 2024Article
- Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern.bioRxiv : the preprint server for biology · 2024Article
147 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
28 authors at 9 institutions in 2 countries.
Christoph KreerLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Matthias ZehnerLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Timm WeberLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Meryem S ErcanogluLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Lutz GieselmannLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Cornelius RohdeInstitute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany.
Sandro HalweInstitute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany.
Michael KorenkovLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Philipp SchommersLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Kanika VanshyllaLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Veronica Di CristanzianoInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.
Hanna JanickiLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Reinhild BrinkerDepartment I of Internal Medicine, Center for Integrated Oncology (CIO) Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany.
Artem AshurovLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Verena KrählingInstitute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany.
Alexandra KupkeInstitute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany.
Hadas Cohen-DvashiDepartment of Structural Biology, Weizmann Institute of Science, 76100 Rehovot, Israel.
Manuel KochInstitute for Dental Research and Oral Musculoskeletal Biology and Center for Biochemistry, University of Cologne, 50931 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Jan Mathis EckertFaculty of Medicine, University of Würzburg, 97080 Würzburg, Germany.
Simone LedererInstitute for Translational Bioinformatics, University Hospital Tübingen and University of Tübingen, 72076 Tübingen, Germany.
Nico PfeiferFaculty of Medicine, University of Tübingen, 72076 Tübingen, Germany; Methods in Medical Informatics, Department of Computer Science, University of Tübingen, 72076 Tübingen, Germany; German Center for Infection Research, Partner Site Tübingen, 72076 Tübingen, Germany.
Timo WolfDepartment of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany.
Maria J G T VehreschildDepartment of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany.
Clemens WendtnerDepartment of Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig Maximilians University, 80804 Munich, Germany.
Ron DiskinDepartment of Structural Biology, Weizmann Institute of Science, 76100 Rehovot, Israel.
Henning GruellLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany.
Stephan BeckerInstitute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany.
Florian KleinLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. Electronic address: florian.klein@uk-koeln.de.
University of Cologne · DEUniversity Hospital Cologne · DEPhilipps University of Marburg · DEUniversity Hospital Frankfurt · DEWeizmann Institute of Science · ILGerman Center for Infection Research · DEMünchen Klinik Schwabing · DEUniversity of Tübingen · DEUniversity of Würzburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 with IC
Indexed as
Antibodies, NeutralizingAntibodies, ViralBetacoronavirusB-LymphocytesCoronavirus InfectionsCOVID-19HumansImmunoglobulin Variable RegionImmunologic MemoryLongitudinal StudiesPandemicsPneumonia, ViralSARS-CoV-2Somatic Hypermutation, ImmunoglobulinAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Variable Region2019-nCoVCOVID-19monoclonal antibodyneutralizing antibodySARS-CoV-2single B cell analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT04854876ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.